- Home
- VINP vs CRMD Comparison
VINP vs CRMD Comparison
Compare VINP & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VINP | CRMD |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 702.6M | 509.9M |
| IPO Year | 2020 | 2009 |
Fundamental Metrics
Financial Performance| Metric | VINP | CRMD |
|---|---|---|
| Price | $10.03 | $6.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $14.00 | ★ $14.67 |
| AVG Volume (30 Days) | 74.2K | ★ 1.5M |
| Earning Date | 03-04-2026 | 03-05-2026 |
| Dividend Yield | ★ 6.08% | N/A |
| EPS Growth | N/A | ★ 780.00 |
| EPS | N/A | ★ 2.04 |
| Revenue | N/A | ★ $311,709,000.00 |
| Revenue This Year | $20.11 | $0.30 |
| Revenue Next Year | $16.18 | N/A |
| P/E Ratio | $24.41 | ★ $3.28 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $8.66 | $5.60 |
| 52 Week High | $13.61 | $17.43 |
Technical Indicators
Market Signals| Indicator | VINP | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 32.58 | 47.74 |
| Support Level | $9.35 | $6.55 |
| Resistance Level | $10.10 | $7.44 |
| Average True Range (ATR) | 0.51 | 0.23 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 19.50 | 67.54 |
Price Performance
Historical ComparisonAbout VINP Vinci Partners Investments Ltd.
Vinci Compass Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.